Search
Pralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.
Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acidIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions
Categories: Compounds used in a research, industrial, or household settingPoliglusam
go.drugbank.com/drugs/DB11234ApprovedInvestigationalIn comparison, commercial poliglusam is derived from deacetylation of chitin contained in the shells of various sea crustaceans such as shrimps [L999]. … As a rich source of dietary fiber, chitosan is used as a food ingredient or additive.
Mixtures: Ariella Nail Repair PenCategories: Compounds used in a research, industrial, or household settingSelenium Sulfide
go.drugbank.com/drugs/DB00971ApprovedSelenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. … Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrheic dermatitis and tinea capitis, a fungal infection that is primarily a disease of preadolescent
Products: Selsun Blue 2-in-1, Selsun Blue, 2-IN-1Felbamate
go.drugbank.com/drugs/DB00949ApprovedAlternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Hyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Vecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … [A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory